Response to Letter Regarding Article, "heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial"

Circulation

Volumn 132, Issue 6, 2015, Pages e121-e122

  Scirica, Benjamin M ^a   Braunwald, Eugene ^a   Raz, Itamar ^b   Cavender, Matthew A ^a   Morrow, David A ^a   Jarolim, Petr ^a   Udell, Jacob A ^c   Mosenzon, Ofri ^b   Im, Kyungah ^a   Umez Eronini, Amarachi A ^a   Pollack, Pia S ^d   Hirshberg, Boaz ^d   Frederich, Robert ^e   Lewis, Basil S ^f   McGuire, Darren K ^g   Davidson, Jaime ^g   Steg, Gabriel ^h,i   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TORONTO   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e BRISTOL MYERS SQUIBB   (United States)

^f CARMEL MEDICAL CENTER   (Israel)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h BICHAT HOSPITAL   (France)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE;

BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; FEMALE; HEART FAILURE; HUMANS; MALE;

EID: 84939457713     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.015511     Document Type: Letter

References (3)

1. Devin JK, Pretorius M, Nian H, Yu C, Billings FT 4th, Brown NJ. Substance P increases sympathetic activity during combined angiotensinconverting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension. 2014;63:951-957. doi: 10.1161/HYPERTENSIONAHA.113.02767.
2. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728-733. doi: 10.1161/HYPERTENSIONAHA.110.156554.
3. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-1588. doi: 10.1161/CIRCULATIONAHA.114.010389.